In vitro Effect of Dalteparin and Argatroban on Hemostasis in Critically Ill Sepsis Patients with New-Onset Thrombocytopenia
TH Open · 01.01.2023 · 07 (01) · e42-e55
DOI: 10.1055/a-2000-6576 ↗Kurz gefasst
Fachartikel in der Zeitschrift TH Open, erschienen am 01.01.2023. Verfasst von Søren Nygaard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Thrombosis and Hemostasis Research Unit, Aarhus University Hospital, Aarhus, Denmark. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aarhus Universitets Forskningsfond.
Themen: Sepsis
Abstract (Originalsprache)
Thrombocytopenia is common among critically ill sepsis patients, while they also hold an increased risk for thromboembolic events. Thus, the choice of anticoagulant prophylaxis for this patient population is challenging. We investigated the in vitro effect of low-molecular-weight heparin (dalteparin) and direct thrombin inhibitor (argatroban) on the hemostasis in blood from sepsis patients with new-onset thrombocytopenia. Thrombocytopenia was defined as a platelet count drop of ≥30% and/or from >100 × 109/L to 30 to 100 × 109/L within 24 hours prior to inclusion. We included five healthy individuals and ten patients. Analyses of thrombin generation (Calibrated Automated Thrombogram), thrombin-antithrombin (TAT) complex levels, prothrombin fragment 1+2 (F1+2), and rotational thromboelastometry (ROTEM) were performed. Based on dose–response relationships investigated in healthy blood, patient samples were spiked with prophylactic (0.25 IU/mL) and therapeutic (0.75 IU/mL) dalteparin and low (0.25 µg/mL) and high (0.50 µg/mL) argatroban concentrations, each with a sample without anticoagulant. In patients, the endogenous thrombin potential was markedly lower in therapeutic dalteparin samples than in samples without anticoagulant [median (range): 29 (0–388) vs. 795 (98–2121) nM × min]. In high argatroban concentration samples, thrombin lag time was longer than in samples without anticoagulant [median (range): 15.5 (10.5–20.2) versus 5.3 (2.8–7.3) min]. Dalteparin and argatroban both increased clotting time but did not affect maximum clot firmness in the ROTEM INTEM assay. Six patients had elevated TAT and eight patients had elevated F1 + 2. In conclusion, dalteparin mainly affected the amount of thrombin generated and argatroban delayed clot initiation in critically ill sepsis patients with new-onset thrombocytopenia. Neither anticoagulant affected clot strength.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, Thrombosis and Hemostasis Research Unit, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Anesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark.
- Faculty of Health, Aarhus University, Aarhus, Denmark.
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Biochemistry, Gødstrup Regional Hospital, Herning, Denmark.
ORCID-Profile: Anne-Mette Hvas
Förderung
- Aarhus Universitets Forskningsfond
Zitieren
APA
Nygaard, S., Hvas, C. L., Hvas, A. M., & Adelborg, K. (2023). In vitro Effect of Dalteparin and Argatroban on Hemostasis in Critically Ill Sepsis Patients with New-Onset Thrombocytopenia. TH Open, 07(01), e42-e55. https://doi.org/10.1055/a-2000-6576
Vancouver
Nygaard S, Hvas CL, Hvas AM, Adelborg K. In vitro Effect of Dalteparin and Argatroban on Hemostasis in Critically Ill Sepsis Patients with New-Onset Thrombocytopenia. TH Open. 2023;07(01):e42-e55. doi:10.1055/a-2000-6576
BibTeX
@article{Nygaard2023,
author = {Nygaard, Søren and Hvas, Christine L and Hvas, Anne-Mette and Adelborg, Kasper},
title = {In vitro Effect of Dalteparin and Argatroban on Hemostasis in Critically Ill Sepsis Patients with New-Onset Thrombocytopenia},
journal = {TH Open},
year = {2023},
volume = {07},
number = {01},
pages = {e42--e55},
doi = {10.1055/a-2000-6576}
}
EUVIMED